莱斯康制药 LXRX 深 沪
已收盘 10-31 16:00:00 美东时间
1.38
+0.040
+2.99%
华盛通- 最 高1.40
- 今 开1.35
- 成交量 111.12万股
- 最 低 1.3401
- 昨 收 1.34
- 总市值 5.01亿
- 52周最高 1.66
- 市盈率 静 --
- 换手率 0.31%
- 52周最低 0.2836
- 委 比 -93.76%
- 总股本 3.63亿
- 历史最高 22.96
- 量 比 0.69
- 振 幅 4.47%
- 历史最低 0.2836
- 每 手 1
- 风险率 0.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
Lexicon Pharmaceuticals will release its Q3 2025 financial results on November 6, 2025, followed by a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a business update. Participants can access the call via webcast on the company’s website or register to receive dial-in details. Lexicon is a biopharmaceutical company focused on pioneering medicines through its Genome5000™ program, targeting proteins with therapeutic ...
10-30 12:30
Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement
Lexeo Therapeutics announced an underwritten public offering and concurrent private placement, raising approximately $135 million in gross proceeds. The company offered 15,625,000 shares of common stock at $8.00 per share, with an option for underwriters to purchase an additional 2,343,750 shares. Additionally, Lexeo sold pre-funded warrants for 1,250,015 shares of common stock to Balyasny Asset Management at $7.9999 per warrant in a private plac...
10-17 03:29
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
Lexicon Pharmaceuticals announced Phase 2 data supporting the advancement of 10 mg pilavapadin into Phase 3 development for diabetic peripheral neuropathic pain (DPNP). The U.S. FDA accepted the company's request for an end-of-Phase 2 meeting, and discussions with potential partners are progressing. Key findings include validated biological activity, clinically meaningful efficacy (2-point ADPS reduction), and acceptable tolerability and safety p...
10-14 12:00
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain
Lexicon hosted a roundtable to discuss improving access to non-opioid treatments and expanding legislation like the Alternatives to PAIN Act for chronic pain patients. The meeting focused on addressing the high impact of chronic pain, affecting 50 million Americans, and highlighted the need for innovative therapies and policy changes.
10-08 11:59
Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings
In the PROGRESS Phase 2b study, Lexicon Pharmaceuticals' investigational AAK1-inhibitor, pilavapadin, showed a two-point reduction from baseline in average daily pain scores (ADPS) by week 11 for the treatment of diabetic peripheral neuropathic pain (DPNP). The 10 mg dose was well-tolerated and identified as the most clinically meaningful dose. Results were presented at the NEUROdiab and EASD Annual Meetings, highlighting pilavapadin's potential ...
09-17 11:00
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
Lexicon Pharmaceuticals is presenting clinical data on pilavapadin, an investigational AAK1 inhibitor for diabetic peripheral neuropathic pain (DPNP), at three medical meetings. The first presentation will be at NeuroDiab on September 13, 2025, followed by EASD on September 17, 2025, and Arrowhead’s Pain Summit on October 13, 2025. Rodica Pop-Busui, M.D., Ph.D., will present at the first two meetings, while Suma Gopinathan, Ph.D., will present th...
09-11 12:30
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
<p>Lexicon Pharmaceuticals submitted additional clinical data to the FDA from third-party funded studies to address concerns raised in the December 2024 complete response letter regarding Zynquista's potential risks. The data aims to support the resubmission of the New Drug Application for Zynquista as a treatment for adults with type 1 diabetes. FDA feedback is expected by the end of September. The company acknowledges strong patient support for...
09-08 12:30
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
<p>Lexicon Pharmaceuticals will present new data on pilavapadin, an AAK1 inhibitor, showing its effectiveness in reducing neuropathic pain in preclinical models of chemotherapy-induced peripheral neuropathy (CIPN) and multiple sclerosis (MS) at the 9th International Congress on Neuropathic Pain in Berlin. The findings suggest the potential of pilavapadin for treating additional neuropathic pain conditions beyond diabetic peripheral neuropathic pa...
09-04 12:30
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
Lexicon Pharmaceuticals will present data on the physical and psychological impact of diabetic peripheral neuropathic pain (DPNP) at PAINWeek 2025. The study highlights patient experiences despite using available pain relievers and aims to inform the development of pilavapadin, a potential treatment for DPNP. Pilavapadin, a selective AAK1 inhibitor, received Fast Track designation from the FDA. Lexicon is focused on advancing innovative therapies...
09-03 12:30
美股大行评级 | 潜在涨幅91.64%！曼恩凯德生物医疗获HC Wainwright升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持曼恩凯德生物医疗"买入"评级，目标价从9美元升至11美元；杰富瑞：维持Ionis Pharmaceuticals"买入"评级，目标价从83美元升至96美元
09-03 10:20
